Tumor Necrosis Factor Induces von Willebrand Factor Release in Healthy Humans

Tom van der Poll; Sander J H van Deventer; Gerard Pasterkamp; Jan A van Mourik; Harry R Büller; Jan W ten Cate

doi:10.1055/s-0038-1648512

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1992; 67(06): 623-626
DOI: 10.1055/s-0038-1648512

Original Articles

Schattauer GmbH Stuttgart

Tumor Necrosis Factor Induces von Willebrand Factor Release in Healthy Humans

Autoren

Tom van der Poll

¹The Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

²Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Sander J H van Deventer

¹The Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

²Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Gerard Pasterkamp

³Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
Jan A van Mourik

³Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
Harry R Büller

²Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Jan W ten Cate

²Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Abstract

als PDF herunterladen

Summary

Tumor necrosis factor (TNF) is an important mediator of the host responses to systemic infection. To investigate the effect of TNF on the release of von Willebrand factor (vWF) into the circulation, we performed a controlled study in six healthy men, sequentially measuring the plasma concentrations of vWF antigen after a bolus intravenous injection of recombinant human TNF (50 μg/m²). TNF induced a marked increase in vWF antigen plasma levels, becoming significant after 45 min and peaking after 4 h (percentage increase from base line: 351 ±46; p <0.0001, TNF versus saline). The multimeric organization of circulating vWF was not affected by TNF. We conclude that TNF may be an early mediator of increased vWF secretion in systemic infection.

PDF (1151 kb)

Referenzen

References
1 Foster PA, Zimmerman TS. Factor VIII structure and function. Blood Rev 1989; 3: 180-191
2 Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-394
3 Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86: 474-480
4 Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183-192
5 Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino Jr MA, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147-153
6 Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486
7 Van Deventer SJH, Biiller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
8 Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KR, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 p and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-1633
9 Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664
10 Harlan JM, Harker LA, Striker GE, Weaver LJ. Effects of lipopoly-saccharide on human endothelial cells in culture. Thromb Res 1983; 29: 15-26
11 Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-197
12 Booth F, Allington MJ, Cederholm-Williams SA. An in vitro model for the study of acute release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 71-78
13 Giddings JC, Shall L. Enhanced release of von Willebrand factor by human endothelial cells in culture in the presence of phorbol myristate acetate and interleukin 1. Thromb Res 1987; 47: 259-267
14 Zavoico GB, Ewenstein BM, Schafer AI, Pober JS. IL-1 and related cytokines enhance thrombin-stimulated PGI₂ production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. J Immunol 1989; 142: 3993-3999
15 Paleolog EM, Crossmann DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990; 75: 688-695
16 Tannenbaum SH, Gralnick HR. ³-Interferon modulates von Willebrand factor release by cultured human endothelial cells. Blood 1990; 75: 2177-2184
17 Gralnick HR, McKeown LP, Wilson OM, Williams SB, Elin RJ. Von Willebrand factor release induced by endotoxin. J Lab Clin Med 1989; 113: 118-122
18 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
19 Van der Poll T, Biiller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627
20 Van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Biiller HR, ten Cate JW. Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 693-698
21 Cejka J. Enzyme immunoassay for factor VUI-related antigen. Clin Chem 1982; 2: 1356-1358
22 Ruggeri ZM, Zimmermann TS. The complex multimeric composition of factor VUI/von Willebrand factor. Blood 1981; 57: 1140-1143
23 Sherry B, Cerami A. Cachectin/tumor necrosis factor exerts endocrine, paracrine and autocrine control of inflammatory responses. J Cell Biol 1988; 107: 1269-1277
24 Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355-357
25 Girardin E, Grau GE, Dayer J-M, Roux-Lombard P. the J5 study group, Lambert P-H. Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397-400
26 Bowie EJW, Solberg LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe von Willebrand’s disease. J Clin Invest 1986; 78: 26-30
27 Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79: 117-123
28 de Groot PG, Gonsalves MD, Loesberg C, van Buul-Wortelboer MF, van Aken WG, van Mourik JA. Thrombin-induced release of von Willebrand factor from endothelial cells is mediated by phospholipid methylation. J Biol Chem 1984; 259: 13329-13333
29 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VUI/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand diseases subtypes. Blood 1982; 59: 1272-1278